Pzena U.S. Large Cap Value ETF
PZLV - ETF AI Analysis
Top Page
Pzena U.S. Large Cap Value ETF (PZLV)
PZLV’s rating suggests it is a solid but not outstanding value-focused ETF, with its performance driven by a mix of strong and weaker large-cap holdings. Strong contributors like Universal Health Services and Dollar General support the fund with solid financial performance, positive outlooks, and generally favorable technical trends, while holdings such as Baxter International and Robert Half, which face financial and operational challenges and bearish technical signals, likely weigh on the overall rating. The main risk factor is the fund’s exposure to several companies showing profitability pressures, leverage concerns, and negative price trends, which can increase volatility and downside risk for investors.
PZLV vs. SPDR S&P 500 ETF (SPY)
- AUM
- 73.18M
- Region
- North America
- Expense Ratio
- 0.60%
- Beta
- 0.31
- Issuer
- Pzena
- Inception Date
- Apr 01, 2026
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
PZLV Summary
Pzena U.S. Large Cap Value ETF (PZLV) is an actively managed fund that focuses on large, established U.S. companies that appear undervalued based on their earnings and assets. It follows a value investing theme rather than tracking a fixed index, with major holdings in sectors like health care, financials, and technology. Well-known companies in the fund include CVS Health and Humana. Investors might consider PZLV if they want long-term growth by investing in solid companies that may be temporarily out of favor. A key risk is that value stocks can stay cheap for a long time, and the ETF’s price can go up and down with the overall stock market.
How much will it cost me?
This ETF has an expense ratio of 0.60%, which means you’ll pay about $6 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed, paying a professional team to research and pick value stocks rather than simply tracking an index.
What would affect this ETF?
This ETF could benefit if the U.S. economy stays healthy, interest rates stabilize or fall, and investor sentiment shifts toward value stocks, which may help its large health care, financial, and technology holdings as well as companies like Baxter, Humana, and Wells Fargo. On the downside, higher interest rates, pressure on bank profits, changes to health care regulation, or a slowdown in consumer spending could hurt its financial and health care exposure and weigh on top holdings such as CVS, Capital One, and Dollar General.
PZLV Top 10 Holdings
PZLV is leaning hard into U.S. health care and financial value names, and that’s where most of the action is. Humana has been a clear bright spot, rising steadily and giving the fund a healthy tailwind, while CDW and Tyson Foods are also quietly pulling their weight. On the flip side, Baxter and Fresenius Medical Care look more like problem children, with mixed to lagging trends that cap some of the upside. Cognizant’s rebound efforts remain uneven, underscoring that this is a concentrated, U.S.-only value bet with a few key stocks setting the tone.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Baxter International | 5.06% | $3.70M | $13.35B | 38.02% | 45Neutral | |
| Corebridge Financial, Inc. | 4.66% | $3.41M | $15.94B | 24.79% | 67Neutral | |
| Humana | 4.33% | $3.17M | $54.05B | 90.08% | 69Neutral | |
| Fresenius Medical Care | 3.80% | $2.78M | $11.75B | -7.05% | 65Neutral | |
| CDW | 3.50% | $2.56M | $21.42B | 16.97% | 62Neutral | |
| Universal Health | 3.33% | $2.44M | $11.19B | -14.72% | 74Outperform | |
| CVS Health | 3.23% | $2.37M | $114.32B | 12.76% | 64Neutral | |
| Robert Half | 3.18% | $2.32M | $4.30B | 52.84% | 60Neutral | |
| Tyson Foods | 3.11% | $2.27M | $20.28B | 8.32% | 69Neutral | |
| Dollar General | 3.06% | $2.24M | $29.59B | 28.75% | 73Outperform |
PZLV Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PZLV, the sentiment is Positive. The current price of 32.15 is above the 20-day moving average (MA) of 31.78, above the 50-day MA of 31.07, and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.34 indicates Negative momentum. The RSI at 57.94 is Neutral, neither overbought nor oversold. The STOCH value of 59.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PZLV.
PZLV Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $32.15 | $35.00(8.85% Upside) | $73.18M | 0.60% | 68Neutral | |
| $36.83 | $42.31(14.89% Upside) | $97.40M | 0.36% | 72Outperform | |
| $141.05 | $167.40(18.68% Upside) | $93.69M | 0.75% | 74Outperform | |
| $26.14 | $29.70(13.63% Upside) | $74.39M | 0.38% | 72Outperform | |
| $14.29 | $16.27(13.87% Upside) | $69.44M | 0.55% | 73Outperform | |
| $32.21 | $34.70(7.74% Upside) | $48.85M | 0.58% | 68Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PZLV | Pzena U.S. Large Cap Value ETF | 32.15 | 7.05 | 28.09% | |
| PRXV | Praxis Impact Large Cap Value ETF | 36.83 | 7.96 | 27.58% | |
| MAVF | Matrix Advisors Value ETF | 141.05 | 25.95 | 22.55% | |
| NSIV | North Square Disciplined Value ETF | 26.14 | 1.05 | 4.20% | |
| DHLX | Diamond Hill Large Cap Concentrated ETF | 14.29 | 1.76 | 14.07% | |
| MDLV | Morgan Dempsey Large Cap Value ETF | 32.21 | 5.04 | 18.53% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
